![Thomas Lynch lists his areas of emphasis at the Hutch: Solid tumors, immuno-oncology, big data, microbial involvement](https://cdn.cancerletter.com/media/2020/01/25191749/Hutch_4x3.jpg)
![Thomas Lynch lists his areas of emphasis at the Hutch: Solid tumors, immuno-oncology, big data, microbial involvement](https://cdn.cancerletter.com/media/2020/01/25191749/Hutch_4x3.jpg)
Cover Story
Conversation with The Cancer LetterFree
On Feb. 1, Thomas J. Lynch will report to work as president and director of Fred Hutchinson Cancer Research Center.
By Alexandria Carolan
By Alexandria Carolan
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital
- Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”